Pluvicto is a medicine used to treat prostate cancer that has spread. It finds a marker called PSMA on prostate cancer cells and delivers a small dose of radiation right to them. It's given as an infusion into a vein at a hospital or clinic.
Every report comes from a Lived member, sent anonymously.
Have you tried Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan) for Castration-Resistant Prostate Cancer?
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a radioactive medicine for adults with prostate cancer that has spread beyond the prostate (metastatic prostate cancer). It works only when the cancer carries a marker called prostate-specific membrane antigen (PSMA), so a special scan is needed first to show that it does. It is approved in two situations. For cancer that has not yet been treated with hormone therapy, or that still responds to it, Pluvicto is given together with an androgen receptor pathway inhibitor (ARPI). ARPIs are hormone-blocking pills, such as abiraterone, enzalutamide, apalutamide and darolutamide, that cut off the testosterone signals prostate cancer uses to grow. For cancer that has kept growing despite an ARPI, Pluvicto can be used on its own, either as a way to put off taxane chemotherapy or after that chemotherapy has already been tried. In a large trial of men whose cancer had progressed after both an ARPI and chemotherapy, those given Pluvicto lived a median of about 15 months, compared with about 11 months on standard care alone, and about half of those with measurable tumors saw them shrink. In earlier settings, studies show it delays the point at which scans show the cancer growing; whether it also extends life when added to an ARPI earlier in the disease is not yet known.
Pluvicto pairs a radioactive metal, lutetium-177, with a small molecule that latches onto PSMA, a protein found on the surface of prostate cancer cells. After it is injected into a vein, the medicine travels through the bloodstream and sticks to cells displaying PSMA, wherever they are in the body. Once attached, the lutetium-177 gives off beta radiation, a short-range form of radiation that reaches only a couple of millimeters into tissue. It damages the DNA of the cancer cells and some cells right next to them, which can cause those cells to die. Because the radiation travels so short a distance, it can treat many spread-out tumors at once while sparing most of the body, though some normal tissues, notably the salivary glands, tear glands and kidneys, also take up the medicine and receive radiation. The body clears most of what does not bind through the urine.
Before treatment, a PSMA PET (positron emission tomography) scan, an imaging test using a small amount of a radioactive tracer that also binds PSMA, shows whether the cancer has enough of the marker for Pluvicto to work. Pluvicto is given in a hospital or clinic nuclear medicine department by staff trained to handle radioactive medicines. Each dose goes into a vein through an IV line, either as a slow injection over a few minutes or as an infusion of about half an hour. Doses are usually given every 6 weeks for up to 6 doses, so a full course spans about 7 months. Treatment can stop sooner if the cancer grows or side effects become too much. Testosterone-lowering treatment with a GnRH analog (a medicine that keeps the body from making testosterone) continues throughout, unless the testicles have already been surgically removed. People in the earlier, hormone-sensitive setting also keep taking their ARPI pills. Drinking extra fluids and urinating often before and after each dose helps move the unbound medicine out of the body and limits radiation to the bladder and kidneys. Blood counts or kidney problems can lead the team to delay a dose, lower it, or stop treatment.
Tiredness and dry mouth are the most common effects, each affecting about half of people in clinical trials. Dry mouth happens because the salivary glands absorb some of the medicine, and in trials it was rarely severe. Nausea affects about a third, and some people notice a lower appetite, vomiting, constipation or a change in taste. The more serious risks are to the bone marrow and the kidneys. Pluvicto often lowers blood counts, and occasionally the drop is severe: low red cells cause fatigue and breathlessness, low platelets cause bleeding, and low white cells make infections more dangerous. In trials, a small number of people died from bleeding or infection linked to very low counts. Contact the care team promptly about unusual bruising or bleeding that is hard to stop, fever, chills, frequent infections, mouth sores, or new weakness, pale skin or shortness of breath. Kidney damage is less common but can be serious, so contact the team promptly if you are urinating much less often or passing much smaller amounts than usual. People aged 75 and older had more serious side effects in trials, and kidney problems before treatment also raise the risk.
Because Pluvicto is radioactive, people around you receive a small amount of radiation for several days after each dose. The label advises staying more than 3 feet away from others for 2 days, and from children and pregnant women for 7 days; avoiding sex for 7 days; and sleeping in a separate room from other adults for 3 days, from children for 7 days and from a pregnant woman for 15 days. The care team gives detailed instructions before you go home. The radiation can harm a developing baby. Men whose partners could become pregnant should use effective contraception during treatment and for 14 weeks after the last dose. Pluvicto can also cause infertility, which may be permanent, so anyone hoping to have children should discuss fertility options with the team before starting. The medicine adds to a person's lifetime radiation exposure, which carries a small long-term increase in cancer risk. Pluvicto has no listed contraindications and no specific drug interactions in its label, but the team should still know about every medicine and supplement you take, especially anything that affects the kidneys or blood counts.
Each treatment visit ends with radiation safety instructions before you go home. Blood counts and kidney tests are checked before and during treatment, and follow-up scans and tests track how the cancer is responding. Responses vary widely: some people's tumors shrink substantially and others see little benefit, and the scan used beforehand helps select those most likely to respond. The aim is to slow the cancer and, in advanced disease, to extend life. If the cancer grows during or after treatment, the team will discuss other options.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan), what you've noticed, or ask the community a question.